Article
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
International journal of hematology - 1 Jun 2018
Naqvi Kiran, Cortes Jorge E, Luthra Raja, O'Brien Susan, Wierda William, Borthakur Gautam, Kadia Tapan, Garcia-Manero Guillermo, Ravandi Farhad, Rios Mary Beth, Dellasala Sara, Pierce Sherry, Jabbour Elias, Patel Keyur, Kantarjian Hagop
Abstract excerpt
Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in vitro to all TKI. We aimed to study the incidence, prognosis, and response to treatment in patients with E255K/V. We evaluated 976 patients by sequencing of BCR-ABL1 fusion transcript for ABL1 KD mutations. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.